The Food and Drug Administration has given GSK a ‘priority review’ on the work it’s been doing on a melanoma treatment, which if approved, will see for the first time, the dual use of ‘Tafinlar’ in the treatment of skin cancer.
More needs to be done to educate the general population of the risk of sun and UV exposure, and to influence sunscreen use, after a study revealed that even some melanoma survivors are still not protecting themselves as well as they could.
